ALSO NOTED: Does FDA scrutinize new generics enough?; BMS shops baby-food business;

> Are generics as good as brand-name drugs? The Los Angeles Times questions the FDA's generic-approval process, which leans lightly on drug makers. Report

> Bristol-Myers Squibb is looking to get out of the baby food business, scouting out potential buyers for the $7 billion to $9 billion unit. Report

> Potential buyers have been touring Pfizer's Ann Arbor, MI, facility, which is set to close in 2009. Report

> India's Sun Pharmaceutical Industries got FDA approval for its copycat form of AstraZeneca's Ethyol, used to reduce kidney damage in patients with advanced ovarian cancer. Report

> Teva is planning an aggressive move into biogenerics. Report

> In an interview, Celgene CEO Sol Barer laid out some of the basics in how it will integrate operations with Pharmion, a biotech Celgene paid $2.9 billion for. Report

And Finally... A new book takes Big Pharma to task for marketing tactics. Report

Suggested Articles

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

The role of distributors like AmerisourceBergen, is to ensure patients can get access to therapies, no matter where they present.